Institution Directory

Clinical trials at Penn Medicine (University of Pennsylvania)

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1361

Shown on this page

Current sort

Live official records

Conditions: Myotonic Dystrophy
Interventions: SAR446268; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 10 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 5
States / cities: Gainesville, Florida • Tampa, Florida • New York, New York + 2 more

Conditions: Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
Interventions: BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection, Paclitaxel 80 mg/m2 weekly; Drug
Lead sponsor: BioInvent International AB; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 3
States / cities: Duarte, California • New York, New York • Philadelphia, Pennsylvania

Conditions: Atrial Fibrillation, Stroke, Ischemic, Systemic Embolism
Interventions: WATCHMAN device; Device
Lead sponsor: Hamilton Health Sciences Corporation; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 53
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Fountain Valley, California + 48 more

Conditions: Neoplasms
Interventions: Gene-modified (GM) T cell therapy; Genetic
Lead sponsor: Celgene; Industry
Eligibility: Not listed
Enrollment: 1,541 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2043
U.S. locations: 103
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 75 more

Conditions: Head and Neck Cancer
Interventions: ConformalFLASH irradiation; Radiation
Lead sponsor: IBA Proton Therapy, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension in Pregnancy, Obstetrical Complications
Interventions: Anti-hypertensive medication titrated to a BP goal of <140/90 mmHg, Usual Care: Anti-hypertensive medication for BP ≥160/110 mmHg titrated to a goal of < 160/110 mmHg; Drug · Other
Lead sponsor: The George Washington University Biostatistics Center; Other
Eligibility: 14 Years to 56 Years · Female only
Enrollment: 4,120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more

Conditions: Immune Thrombocytopenic Purpura (ITP)
Interventions: Mezagitamab, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 25
States / cities: Hot Springs, Arkansas • Los Angeles, California • San Diego, California + 21 more

Conditions: Membranous Nephropathy, Nephrotic Syndrome
Interventions: Belimumab, Placebo for Belimumab, Rituximab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Francisco, California + 17 more

Conditions: Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions: SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine, SOC, Antiandrogen; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 6
States / cities: New Haven, Connecticut • Baltimore, Maryland • Rochester, Minnesota + 3 more

Conditions: Retinopathy of Prematurity (ROP)
Interventions: Ultra-widefield Optical Coherence Tomography (UWF-OCT), Wide-field ophthalmic imaging system; Device
Lead sponsor: Duke University; Other
Eligibility: 0 Days to 9 Months
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Emphysema, Pulmonary, Emphysema or COPD
Interventions: AeriSeal System; Device
Lead sponsor: Pulmonx Corporation; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 20
States / cities: Phoenix, Arizona • Loveland, Colorado • Hartford, Connecticut + 13 more

Conditions: Cervical Cancer, Uterine Cancer, Endometrial Cancer
Interventions: Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT); Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Voorhees Township, New Jersey • Lancaster, Pennsylvania • Philadelphia, Pennsylvania

About this Penn Medicine (University of Pennsylvania) institution page

What this page lists: ClinicalTrials.gov records that list Penn Medicine (University of Pennsylvania) in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Penn Medicine (University of Pennsylvania)

Filter and sort this campus

Live official records

A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

The Fourth Left Atrial Appendage Occlusion Study

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

A Pilot Study of Ultra-High Dose Rate (ConformalFLASH®), for Reirradiation of Carcinoma of the Head and Neck

Gestational Hypertension and Preeclampsia Blood Pressure (BP) Treatment Goals Less Than 140/90 vs. Less Than 160/110 mmHg: The GOALPOST Trial

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Belimumab With Rituximab for Primary Membranous Nephropathy

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

PROton Therapy for Post Surgical Treatment of GYNecologic Cancer

About this Penn Medicine (University of Pennsylvania) institution page